The Global Acute Intermittent Porphyria Market is segmented on the basis by diagnosis, by treatment, and by end user. On the basis of treatment, it is segmented into gonadotropin-releasing hormone analogues, prophylactic hematin infusions, and others.
Pune, India -- (SBWIRE) -- 01/10/2018 -- The Acute Intermittent Porphyria Market Scenario:
Acute intermittent porphyria (AIP) is a genetic metabolic disorder. It affects the production of them, the oxygen-binding prosthetic group of hemoglobin. Generally, it is characterized by a deficiency of the enzyme porphobilinogen deaminase.
The major causes of acute intermittent porphyria are abnormal urinary color, anorexia, insomnia, myalgia, and urinary retention. In some cases, AIP develops liver cancer (hepatocellular carcinoma), and some develop kidney failure. Other symptoms include gastrointestinal issues, urinary tract issues, neurological issues, psychiatric issues.
The acute intermittent porphyria market growth is majorly attributed to the increasing prevalence of the metabolic disorders, gastrointestinal issues, urinary tract issues, and healthcare insurance coverage. Moreover, increasing geriatric population will drive the market growth.
Get Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/4713 .
According to the Economic and Social Commission for Asia and the Pacific (ESCAP), in 2016, approximately 12.4% of the population in the region was over 60 years. According to Asian Development Bank, it was estimated that by 2050, 15% of total Malaysian population will be over 65 year old and in China, the elderly population will reach over 300 million by 2050. Thus, the increasing geriatric population in Asia is likely to help the growth of the market over the forecast period.
According to the WHO estimates, neurological disorders are responsible for 4.5%-11% of all illnesses including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.
According to the American Liver Foundation, there is an increasing the prevalence of liver disease in the U.S. from then last few years. It further stated that at least 30 million people have some form of liver disease.
However, availability of expensive treatment and poor reimbursement policies in the developing regions of the world are some of the factors, which may hamper the market growth during the forecast period.
The global acute intermittent porphyria market is expected to grow at a CAGR of 5.6 % during the forecast period 2017-2023.
Acute Intermittent Porphyria Market Intended Audience:
Research and Development (R&D) Companies
Government Research Institute
Academic Institutes and Universities
Medical Research Laboratories
Market Research and Consulting Service Providers
Acute Intermittent Porphyria Market Regional Analysis:
The Americas dominate the global acute intermittent porphyria market owing to well-developed technology, increasing patient with genetic metabolic disorders, high healthcare spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.
Europe holds the second position in the global acute intermittent porphyria market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.
Asia Pacific is the fastest growing acute intermittent porphyria market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare projected to lead to the use of advanced equipment, which, in turn, will increase the market growth of the acute intermittent porphyria in the region.
On the other hand, in the Middle East and Africa, blood disorders have become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.
Order a 125 Pages Premium Single User Copy @ https://www.marketresearchfuture.com/checkout?currency=one_user-USD&report_id=4713
Some of key the players in the market are Dahaner (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (U.S.), Siemens AG (U.S.), ARKRAY, Inc. (Japan), Sysmex Corporation (Japan), ACON Laboratories, Inc. (U.S.).
Major TOC of Acute Intermittent Porphyria Market:
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.4 MACROECONOMIC INDICATORS
Ask Questions to Expertise @ https://www.marketresearchfuture.com/enquiry/4713 .
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.